Personalized tumor vaccine and use thereof for cancer immunotherapy
AssigneesNE1 Inc., National Institute of Health, University of South Bohemia in Ceske Budejovice
InventorsZhengping Zhuang, Rogelio Medina, Herui Wang, Jan Zenka, Karel Pacak, Winson Ho
Life of this patent
Estimating the term…
Abstract
Disclosed herein is a personalized tumor vaccine comprising attenuated cancer cells and a method of using said personalized tumor vaccine to treat cancer.
Claims29
A personalized tumor vaccine comprising:
- (a) a phagocytosis stimulating agent,
- (b) an immunostimulatory adjuvant, and
- (c) attenuated cancer cells,
- wherein the personalized tumor vaccine, when administered to an individual in need thereof, is effective to activate an immune response.
(canceled)
(canceled)
(canceled)
-19. (canceled)
-22. (canceled)
A personalized tumor vaccine comprising:
- (a) a mannan, wherein the mannan is conjugated to a BAM,
- (b) a R-848, a poly (I:C), and an LTA,
- (c) an anti-CD40 antibody,
- (d) irradiated cancer cells,
- wherein the personalized tumor vaccine, when administered to an individual in need thereof, is effective to activate an immune response.
A method for treating cancer, comprising administering to an individual in need thereof an effective amount of pharmaceutical composition, wherein the pharmaceutical composition comprises:
- (a) a phagocytosis stimulating agent,
- (b) an immunostimulatory adjuvant, and
- (c) attenuated cancer cells.
(canceled)
(canceled)
-34. (canceled)
-47. (canceled)
Dependencies are inferred from the claim text.